Neurocrine Biosciences Stock in Brief

By Tamara Parker • Monday, December 16 10:14 • Permanent Link

Large-cap Health Care company Neurocrine Biosciences has moved 5.5% so far today on a volume of 294,969, compared to its average of 896,546. In contrast, the S&P 500 index moved 0.0%.

Neurocrine Biosciences trades -18.25% away from its average analyst target price of $163.46 per share. The 26 analysts following the stock have set target prices ranging from $121.0 to $192.0, and on average have given Neurocrine Biosciences a rating of buy.

Anyone interested in buying NBIX should be aware of the facts below:

Neurocrine Biosciences's current price is 20.6% above its Graham number of $110.82, which implies that at its current valuation it does not offer a margin of safety
Neurocrine Biosciences has moved 5.7% over the last year, and the S&P 500 logged a change of 27.6%
Based on its trailing earnings per share of 3.75, Neurocrine Biosciences has a trailing 12 month Price to Earnings (P/E) ratio of 35.6 while the S&P 500 average is 29.3
NBIX has a forward P/E ratio of 21.5 based on its forward 12 month price to earnings (EPS) of $6.21 per share
Its Price to Book (P/B) ratio is 4.97 compared to its sector average of 3.53
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
Based in San Diego, the company has 1,700 full time employees and a market cap of $13.53 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.